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Abstract Previous reports have associated hyperglycemia to
poor outcome among aged and comorbid Staphylococcus
aureus bacteraemia (SAB) patients. However, the prognostic
impact of hyperglycemia in SAB irrespective of age and un-
derlying conditions including a diagnosis of diabetes has re-
ceived little attention. The objective here was to evaluate the
prognostic relevance of hyperglycemia at onset of methicillin-
sensitive SAB (MS-SAB). It was a retrospective study of MS-
SAB patients. Blood glucose was measured within 24 h of
positive blood cultures. The patient cohort was analyzed en
bloc and by categorization according to age, underlying con-
ditions and a diagnosis of diabetes. Altogether 161 patients
were identified. High initial blood glucose levels were ob-
served among diabetics (p < 0.001), patients with deep infec-
tions (p < 0.05) and poor outcome at 28- or 90-days (p < 0.05).
Receiver operating characteristics presented the glucose cut-
off level of 7.2 mmol/L as a significant predictor of mortality
with an area under the curve of 0.63 (95% CI 0.52–0.75,
p < 0.05). Blood glucose ≥7.2 mmol/L connected to higher
28- (9 vs. 20%, p < 0.05) and 90-day (14 vs. 29%, p < 0.01)
mortality. In Cox proportional hazard regression the blood
glucose cut-off value of 7.2 mmol/L significantly predicted
90-day mortality (HR, 2.12; 95% CI, 1.01–4.46; p < 0.05).
Among young and healthy non-diabetics the negative prog-
nostic impact of high glucose was further accentuated (HR
7.46, p < 0.05). High glucose levels had no prognostic impact
among diabetics. Hyperglycemia at SAB onset may associate
to poor outcome. The negative prognostic impact is accentu-
ated among young and healthy non-diabetics.
Introduction
Staphylococcus aureus is one of the leading bloodstream path-
ogens and a major cause of both community- and healthcare-
associated bacteraemias (SAB) [1, 2]. Parameters such as se-
vere sepsis [3], deep infection foci, e.g. endocarditis [4, 5] and
methicillin-resistance [4, 6], may impair prognosis whereas
infectious disease specialist consultation [4, 7, 8] is known
to improve outcome. Previous studies have demonstrated a
deep infection focus in up to 70% of SAB patients [5, 7].
However, despite identification of prognostic parameters and
introduction of novel antibiotics [9] the mortality rates remain
high and range from 12 to 35% in recent reports [4, 10, 11].
Severe infections may induce a hyper-metabolic state and
hyperglycemia [12, 13] through mechanisms such as elevated
cytokine and cortisol levels [14, 15] and insulin deficiency
[16]. Hyperglycemia exerts various harmful effects including
a pro-coagulant action [17] and altered polymorphonuclear
leukocyte functions which may hamper leucocyte migration,
adherence, phagocytosis and intracellular killing [18–20]. A
negative prognostic impact of hyperglycemia has been observed
in various infectious diseases such as pneumonia in diabetics
[21] and non-diabetics [22, 23] as well as bacteraemia among
intensive care unit (ICU) patients [13] and more specifically due
to S. aureus [11, 24, 25], Pseudomonas aeruginosa [26] and
other gram-negative bacteria [27] and candidemia [28].
Previous evaluations on the prognostic impact of hypergly-
cemia in SAB have included aged and comorbid patients with
considerable 44–54% occurrence of methicillin-resistance
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[11, 24, 25]. Blood glucose has been recorded either as mean
levels during the first 7 days after SAB onset [24, 25] or on the
day of admission or on the closest day before the blood cul-
tures were drawn [11]. Furthermore, the statistical analyses
have been performed with breakpoints for blood glucose re-
sults determined in advance [11, 24, 25]. However, high age,
comorbidity and MRSA are well known risk factors for poor
outcome [2, 4, 6, 8]. To the best of our knowledge the rele-
vance of hyperglycemia in MS-SAB patient cohorts irrespec-
tive of age and underlying conditions including a diagnosis of
diabetes has not been previously evaluated.
The objective of the present study was to evaluate the im-
pact of hyperglycemia, at onset of MS-SAB, on disease pro-
gression and prognosis. We applied receiver operating charac-
teristics analysis to identify a statistically significant blood
glucose cut-off value for outcome prediction. Lack of
methicillin-resistant S. aureus (MRSA) enabled us to avoid
the impact of differences in empirical antibiotic therapy.
Methods
Study population
This was a retrospective study recruiting all adult patients
(n = 342) from Helsinki University Central Hospital in
Finland with at least one positive blood culture for S. aureus
during 2000–2002 and 2006–2007. Two time-periods were
included to exclude any unknown temporary differences in
personnel or treatment practices. Patients and corresponding
S. aureus isolates were matched by using the unique personal
number given to all residents of Finland. Patient data were
retrieved from both electronic (2006–2007) and written
(2000–2002) hospital archives. Any possible disadvantage
with either information storage pattern was accounted for by
including both paper and electronic hospital records. Five
cases of MRSA bacteraemia were omitted. Patient records
were followed for 90 days. Data collection included gender,
age, bacteraemia acquisition, underlying diseases, and length
and administration route of any antibiotic therapy.
Furthermore, infection focus documentation was based on
clinical suspicion or verified by radiological, bacteriological,
or pathological investigations. Laboratory results and time to
defervescence (axillary temperature below 37.5 °C) were re-
corded. Primary endpoint was mortality at 28 or 90 days.
Secondary endpoints were prevalence of deep infection foci,
time to defervescence and length of hospitalization.
Definitions
Community- and healthcare-associated SAB have been de-
fined previously [7]. Modified Duke criteria were applied to
define endocarditis [29]. Sepsis in connection with
hypotension, hypo-perfusion, or organ failure was classified
as severe sepsis whereas sepsis with arterial hypotension de-
spite adequate fluid resuscitation was defined as septic shock
[30]. McCabes’s criteria were used to classify severity of un-
derlying diseases into healthy and nonfatal or ultimately and
rapidly fatal [31]. Infectious disease specialist consultations
within 7 days of the first positive blood cultures for
S. aureus were documented and categorized into (1) formal
bedside consultation, (2) informal telephone consultation or
(3) no consultation [7].
Antibiotic therapy
Semisynthetic penicillin was defined as the standard antibiotic
therapy. Cefuroxime, clindamycin or vancomycin was given
to patients with contradictions for penicillin. Rifampicin and
fluoroquinolone were provided as additional antibiotic thera-
py. Proper length of antibiotic therapy was defined as intrave-
nous administration for at least 28 days for deep infection
focus and at least 14 days in the absence of any deep infection.
Antibiotic indications, dosage and administration routes have
been provided in detail previously [32, 33].
Blood glucose
Blood glucose was measured in connection with, shortly be-
fore or shortly after blood culture collecting time-points such
that all glucose samples were measured within 24 h of blood
culture collection.
Statistical analysis
Data is presented either as absolute values and percentages or
as median and interquartile ranges (IQR, 25th and 75th
Fig. 1 The distribution of blood glucose concentrations (mmol/L) among
161 patients with methicillin-sensitive Staphylococcus aureus
bacteraemia within 24 h of blood culture collection
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percentiles). Categorical variables are compared with
Pearson’s X2 -test whereas non-parametric data is analyzed
with Mann–Whitney u-test or Students t-test. Odds ratios
(OR) with 95% confidence intervals (CI) were calculated.
Discriminative power of blood glucose in predicting 90-day
mortality was evaluated by receiver operating characteristic
(ROC) curves. The Youden index was defined as the point
on the ROC-curve maximizing both sensitivity and specificity
values equally to locate the cut-off point. The ROC-curve
derived glucose cut-off point was applied for the Kaplan-
Meier estimator method and for Cox proportional hazard re-
gression model predicting mortality. Univariate factors with
p < 0.05 were allowed for the Cox proportional hazard regres-
sion model. All tests were two-tailed and p < 0.05 was
considered as significant. SPSS version 12.0 (SPSS Inc.,
Chicago, IL, USA) was used for all analyses.
Results
Patient characteristics and blood glucose concentrations
Altogether 342 patients were identified for the study but due
to missing blood glucose samples the results of 161 patients
are shown. Starting from the day of positive blood cultures
each patient was provided with an antibiotic effective in vitro
against the S. aureus blood isolate. Most patients received aβ-
lactam antibiotic whereas a minority was provided with
Table 1 Blood glucose
concentrations (mmol/L) within
24 h of positive blood culture





conditions, severity of illness,
occurrence of deep infection foci
and outcome
Demographics Total N = 161
n (%)
Blood glucose (median + interquartile ranges)
Factor present Factor absent p-value
Male sex 101 (63) 7.00 (5.90–9.11) 7.20 (5.73–8.70) NS
Age > 60 years 58 (36) 7.20 (6.18–10.7) 6.70 (5.80–8.50) NS
Healthcare-associated 68 (42) 7.15 (6.00–8.68) 7.00 (5.80–9.40) NS
Underlying conditiona
Healthy or nonfatalb 117 (73) 6.80 (5.85–8.60) 7.35 (6.03–9.45) NS
Ultimately or rapidly fatalc 44 (27) 7.35 (6.03–9.45) 6.80 (5.85–8.60) NS
Diabetes mellitus 42 (26) 10.4 (6.80–16.8) 6.70 (5.80–7.90) <0.001
Coronary artery disease 31 (19) 7.20 (6.30–9.30) 6.90 (5.80–8.85) NS
Acute or chronic liver disease 37 (23) 6.30 (5.60–8.95) 7.15 (5.90–9.08) NS
Acute or chronic pulmonary disease 22 (14) 7.65 (6.25–9.05) 7.00 (5.80–9.10) NS
Dialysis (haemo or peritoneal) 12 (7) 7.90 (6.78–9.45) 7.00 (5.85–8.90) NS
Pre-bacteraemic corticosteroid c 9 (6) 7.20 (5.50–8.95) 7.00 (5.90–9.08) NS
Rheumatic or connective tissue disease 9 (6) 7.10 (5.05–8.20) 7.00 (5.90–9.18) NS
Non-haematological malignancy 11 (7) 7.20 (5.70–10.1) 7.00 (5.90–8.85) NS
Hematologic malignancy 19 (12) 8.50 (6.70–9.50) 6.95 (5.80–8.70) NS
Severity of illness
Severe sepsisd 29 (18) 7.40 (4.80–8.90) 7.00 (5.90–9.08) NS
Intensive care unitd 56 (35) 7.50 (5.65–8.78) 6.90 (5.90–9.10) NS
Any deep infection 118 (73) 7.20 (5.90–9.30) 6.30 (5.70–7.40) <0.05
Endocarditis 23 (14) 7.40 (5.80–8.80) 7.00 (5.90–9.10) NS
Outcome
Defervescencee 93 (58) 7.00 (5.90–9.15) 7.25 (5.80–9.18) NS
Mortality at 28 days 24 (15) 8.50 (7.00–11.8) 6.70 (5.85–8.60) <0.05
Mortality at 90 days 35 (22) 8.30 (6.40–10.7) 6.70 (5.80–8.65) <0.05
Values are expressed as N (%), unless otherwise stated, or as median and interquartile ranges (25th and 75th
percentiles). p-values calculated with the Mann-Whitney U-test
NS non-significant
a Patients may have ≥ 1 underlying condition
b Classification according to McCabe and Jackson [31]
c Equals prednisolone 10 mg/day for at least 1 month
dAt blood culture collection time-point
e Defervescence within 1 week
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vancomycin (2.5%). The majority of patients received formal
bedside infectious disease specialist consultation (66%)
whereas only 22% had informal telephone consultation.
The mean blood glucose level close to the time point of
positive blood culture drawing was 8.35 ± 4.5 (±SD) mmol/L
and the median blood glucose was 7.00 mmol/L. The distri-
bution of blood glucose levels among patients is presented in
Fig. 1. Patient demographics, bacteraemia acquisition or un-
derlying conditions had no significant impact on blood glu-
cose with the exception of diabetes that associated to signifi-
cantly higher blood glucose levels (p < 0.001) (Table 1).
Severity of illness according to the parameters of severe sepsis
and ICU treatment did not influence the blood glucose level.
A deep infection focus was diagnosed in 73% of patients and
it was associated to significantly higher blood glucose levels
(p < 0.05), although this trend was not observed for endocar-
ditis (Table 1).
Outcome, defervescence and hospitalization
No significant association between blood glucose and time to
defervescence was observed (Table 1). The total case fatality
in 161 patients at 28 days was 15% and at 90 days 22%.Mean
blood glucose levels were significantly higher among patients
who died within 28 or 90 days (Table 1). The mean (±SD)
time of hospitalization for patients that survived was 36 (±32)
days.
Cut-off values for glucose in predicting mortality
By ROC-analysis blood glucose at the time-point for positive
blood cultures was a significant predictor for mortality. The
area under the curve (AUC) in the ROC analysis was 0.63
(95% CI 0.52–0.75, p < 0.05) and produced a cut-off value
of 7.2 mmol/L that predicted 90-day mortality (Fig. 2).
The whole patient cohort was stratified according to the
blood glucose cut-off value of 7.2 mmol/L. A diagnosis of
diabetes (OR 4.47, p < 0.001) was the only demographic pa-
rameter associated with blood glucose levels above the cut-off
value (Table 2). The blood glucose cut-off level connected
significantly to higher 28- (OR 3.01, p < 0.05) and 90-day
(OR 3.12, p < 0.01) mortality. Moreover, patients with blood
glucose < 7.2 mmol/L who survived had significantly shorter
time of hospitalization as compared to those with blood
glucose > 7.2 mmol/L (p < 0.05). Kaplan-Meier analysis for
the whole patient cohort associated patients with blood glu-
cose levels above the cut-off value of 7.2 mmol to significant-
ly higher mortality (log-rank 0.005) (Fig. 3).
Parameters in univariate analysis with significantly elevat-
ed risk for 90-day mortality were severe sepsis (OR 3.35,
p < 0.01), informal telephone infectious disease specialist con-
sultation (OR 2.65, p < 0.05), blood glucose cut-off value of
7.2 mmol/L (OR 3.01, p < 0.01) and age > 60 years (OR 2.28,
p < 0.05). In contrast, lack of severe underlying diseases
(McCabe’s healthy or nonfatal classification) (OR 0.13,
p < 0.001), formal bedside infectious disease specialist consul-
tation (OR 0.15, p < 0.001) and rifampicin therapy for at least
14 days (OR 0.18, p < 0.001) were associated with better
prognosis. In the Cox proportional hazard regression model,
the independent prognostic parameters were age > 60 years
(HR 3.78, p = 0.001), McCabe’s healthy or nonfatal classifi-
cation (HR 0.26, p < 0.001), severe sepsis (HR 2.83, p < 0.01),
rifampicin therapy for at least 14 days (HR 0.23, p = 0.001),
formal bedside infectious disease specialist consultation (HR
0.26, p = 0.001) and a blood glucose cut-off value of
7.2 mmol/L (HR 2.12, p < 0.05) (Table 3).
Furthermore, the Cox proportional hazard regression mod-
el of Table 3 was re-performed with the patient cohort catego-
rized according to age, underlying conditions and a diagnosis
of diabetes. When including only previously healthy
(McCabe’s healthy-nonfatal classification) non-diabetics
(mean age 48.5 ± 17.5 years) the blood glucose cut-off value
of 7.2 mmol/L associated with poor outcome in Cox propor-
tional hazard regression model (HR 7.46, p < 0.05) (Table 4).
However, when including only diabetic patients, irrespective
of underlying conditions or age, the blood glucose cut-off
value of 7.2 mmol/L had no prognostic impact.
Discussion
The main finding of the present study was a poor prognostic
impact associated with hyperglycemia at the time of detection
of SAB. During the 90-days follow-up patients with hyper-
glycemia within 24 h of the blood culture collection time-
Fig. 2 Receiver operating characteristic (ROC) curve for blood glucose
concentration (mmol/L) at blood culture collecting time-point for
predicting 90-day mortality in patients with Staphylococcus aureus
bacteraemia (n = 161). The area under the curve (AUC) was 0.63 (95%
CI 0.52–0.75) (p < 0.05) and the optimal cut-off value 7.2 mmol/L with
sensitivity of 69% and specificity of 58%
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point had more than a 2-fold higher hazard ratio for a fatal
outcome when adjusting for all other prognostic parameters.
The negative prognostic impact of hyperglycemia was accen-
tuated when including only young and previously healthy
non-diabetics. However, hyperglycemia had no prognostic
impact among patients with a diagnosis of diabetes.
Previous studies have identified parameters with indisput-
able prognostic impact in SAB such as old age and underlying
conditions [2, 4, 6], severe sepsis [3] and infectious disease
specialist guided therapy management [4, 7, 8]. Many studies
report the occurrence of diabetes [2, 4, 5, 8, 24, 25, 33] or
other factors that may influence glucose balance, e.g. cortico-
steroid therapy [2, 5, 8, 33]. However, few studies on SAB
report separate laboratory tests, e.g. blood glucose, and to the
best of our knowledge only three reports have evaluated the
impact of glucose balance on outcome in SAB [11, 24, 25].
The results of the present study with a poor prognostic
impact due to hyperglycemia at the initial phase of a severe
infection are in line with many previous reports [11, 22–26,
28]. However, previous studies have applied various measure-
ment time-points and different categorization patterns of
blood glucose. This makes comparison of results challenging.
Some authors report blood glucose levels at hospital admis-
sion or at the closest day before blood culture drawing [11, 22,
23] or report an average blood glucose concentration within
48 h of positive blood cultures [26]. In some reports the mean
Table 2 Patient demographics, underlying conditions, severity of illness and outcome in 161 Staphylococcus aureus bacteraemia patients stratified
according to blood glucose cut-off value 7.20 mmol/L at the time of blood culture collection
Demographics Glucose < 7.2 mmol/L (N = 77) Glucose > 7.2 mmol/L (N = 84) OR (95% CI) p-value
Male sex 55 (71) 46 (55) 0.78 (0.41–1.48) NS
Age > 60 years 26 (34) 32 (38) 1.59 (0.83–3.03) NS
Healthcare-associated 34 (44) 34 (40) 1.16 (0.62–2.18) NS
Underlying conditiona
Healthy or nonfatalb 64 (83) 53 (63) 0.69 (0.34–1.38) NS
Ultimately or rapidly fatalb 20 (26) 24 (29) 1.45 (0.72–2.91) NS
Diabetes mellitus 11 (14) 31 (37) 4.47 (2.05–9.76) <0.001
Coronary artery disease 12 (16) 19 (23) 1.97 (0.88–4.38) NS
Acute or chronic liver disease 22 (29) 15 (18) 0.68 (0.32–1.44) NS
Acute or chronic pulmonary disease 8 (10) 14 (17) 2.11 (0.83–5.35) NS
Dialysis (haemo or peritoneal) 4 (5) 8 (10) 2.32 (0.67–8.03) NS
Pre-bacteraemic corticosteroidc 4 (5) 5 (6) 1.39 (0.36–5.37) NS
Rheumatic or connective tissue disease 5 (6) 4 (5) 0.87 (0.22–3.35) NS
Non-haematological malignancy 5 (6) 6 (7) 1.34 (0.39–4.57) NS
Hematologic malignancy 8 (10) 11 (13) 1.58 (0.60–4.17) NS
Severity of illness
Severe sepsisd 13 (17) 16 (19) 1.43 (0.64–3.21) NS
Intensive care unitd 25 (32) 31 (37) 1.59 (0.83–3.06) NS
Any deep infection 57 (74) 61 (73) 1.81 (0.88–3.69) NS
Endocarditis 11 (14) 12 (14) 1.23 (0.51–2.97) NS
Outcome
Defervescencee 51 (66) 42 (50) 0.76 (0.38–1.52) NS
Mortality at 28 days 7 (9) 17 (20) 3.01 (1.21–8.00) <0.05
Mortality at 90 days 11 (14) 24 (29) 3.12 (1.36–6.67) <0.01
Hospitalization (days) (mean ± SD)f 34 (±19) 44 (±27) – <0.05
Odds ratio (OR) and 95% confidence intervals (95% CI) are presented. Values are expressed as n (%) unless otherwise stated, or mean ± standard
deviation (SD)
NS non-significant
a Patients may have ≥ 1 underlying condition
b Classification according to McCabe and Jackson [31]
c Equals prednisolone 10 mg/day for at least 1 month
dAt blood culture collection time-point
e Defervescence within 1 week
f Students t-test
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blood glucose levels were derived by averaging highest daily
glucose values within the 7 days after infection onset [24, 25,
28] or blood glucose levels from one day prior until 5 days
after onset of infection [13]. Most authors stratify results ac-
cording to blood glucose levels exceeding 167–170 mg/dl (i.e.
9.3–9.4 mmol/L) [11, 24, 25] or the range of 6–13.9 mmol/L
[23, 28]. The ROC analysis in the present study presented a
glucose cut-off value of 7.2 mmol/L that is lower compared to
the breakpoint values applied in previous reports [11, 24, 25,
28]; although one study applied an even lower value of
6.0 mmol/L [23]. To the best of our knowledge, the glucose
breakpoint values in earlier reports have been determined a
priori whereas one study applied a CART-analysis (classifica-
tion and regression tree analysis) to define a breakpoint in the
average concentration of blood glucose in the first 48 h after
positive blood cultures [26]. Thus, as far as we know, the
present study is the first to apply ROC analyses to identify a
statistically significant blood glucose cut-off value for mortal-
ity in severe systemic infections such as SAB.
A recent report observed that hyperglycemia during the
first 7 days among SAB patients resulted more often in dis-
charge to a long-term care facility or inpatient rehabilitation
[25]. The present study did not record discharge addresses.
However, length of hospitalization among patients that sur-
vived was analyzed and hyperglycemia at the initial phase of
SAB associated with significantly longer hospital stay.
Furthermore, previous reports concluded that hyperglycemia
may reflect infection severity and outcome in non-diabetic
patients but not in diabetic patients [34, 35]. The results of
the present study are in line with these two reports as the poor
prognostic impact of hyperglycemia in SAB was accentuated
among previously healthy non-diabetics whereas among
Fig. 3 Kaplan-Meier interpretation for 90-day mortality in patients with
Staphylococcus aureus bacteraemia (n = 161) categorized according to
the receiver operating characteristics (ROC) analysis related blood
glucose cut-off value of 7.2 mmol/L (log-rank 0.005)
Table 3 Cox proportional hazard regression model for prognostic factors of 90-day mortality in Staphylococcus aureus bacteraemia patients (n = 161)
Patient characteristics Univariate analysis Cox regression analysis
Died
N = 35 (22%)
Survived
N = 126 (78%)
OR (95% CI) p-value HR (95% CI) p-value
Male sex 22 (63) 79 (63) 1.01 (0.46–2.19) NS – –
Age > 60 years 18 (51) 40 (32) 2.28 (1.06–4.88) <0.05 3.78 (1.78–8.05) 0.001
Healthy or nonfatal diseasea 13 (37) 104 (83) 0.13 (0.06–0.29) <0.001 0.26 (0.13–0.53) <0.001
Severity of illness
Glucose cut-off 7.2 mmol/Lb 11 (31) 24 (19) 3.01 (1.36–6.67) <0.01 2.12 (1.01–4.46) <0.05
Intensive care unitb 16 (46) 40 (32) 1.81 (0.84–3.89) NS – –
Severe sepsisb 12 (34) 17 (13) 3.35 (1.41–7.95) <0.01 2.83 (1.39–5.78) <0.01
Endocarditis 6 (17) 17 (13) 1.33 (0.48–3.67) NS – –
Pneumonia 19 (54) 49 (39) 1.87 (0.88–3.97) NS – –
Additional antibiotic therapy
Rifampicin therapy ≥ 14 days 8 (23) 78 (62) 0.18 (0.08–0.43) <0.001 0.23 (0.09–0.54) 0.001
Fluoroquinolone therapy 14 (40) 67 (53) 0.59 (0.27–1.26) NS – –
Infectious specialist consultation
Bedside formal consultation 11 (31) 95 (75) 0.15 (0.07–0.34) <0 .001 0.26 (0.12–0.57) 0.001
Telephone informal consultation 13 (37) 23 (18) 2.65 (1.16–6.02) <0.05 – –
Hazards ratio (HR) and 95% confidence intervals (95% CI) are presented. Values are expressed as n (%), unless otherwise stated
NS non-significant
a Classification according to McCabe and Jackson [31]
b At positive blood culture collection time-point
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diabetics the initial blood glucose levels had no influence on
outcome.
To the best of our knowledge, this is the first study evalu-
ating the connection between hyperglycemia determined
within 24 h of positive blood cultures and prognosis among
SAB patients. The patient cohort was stratified according to
ROC analysis derived blood glucose cut-off value and at-
tempts were made to control reasons for differences in out-
come between the various groups. Many of the parameters
with prognostic impact in the present study have been identi-
fied earlier, i.e. age and underlying conditions [2, 4, 6], severe
sepsis [3], adjunctive rifampicin therapy [32] and infectious
disease specialist consultation [7, 36].
Altogether 73% of patients had deep infection foci. This is
in line with the studies presenting deep focus occurrence
among 68–74% of SAB patients [5, 7]. Patients with a deep
infection focus had significantly higher blood glucose levels,
although this difference was not observed for patients with
endocarditis nor when categorizing patients according to the
ROC analysis related cut-off value of 7.2 mmol/L. Our study
is not able to present any explanation for the association be-
tween hyperglycemia at the initial phase of SAB and presence
of a deep infection focus, and diabetics were not overrepre-
sented among patients with a diagnosed deep infection focus.
Previous reports on hyperglycemia and SAB do not comment
on any association between blood glucose and infection foci
[11, 24, 25].
The present study deviates from previous reports on hyper-
glycemia and SAB with respect to age and comorbidity [11,
24, 25]. In the present study only one third of patients were
aged over 60 years and almost three fourths had a healthy- or
nonfatal McCabe’s classification regarding underlying condi-
tions. However, in previous reports the mean age has ranged
from 68 to 72 years with mean Charlson’s comorbidity index
of 1.5–4.6 [11, 24, 25]. Thus, the results of the present study
apply to a younger and less ill patient cohort as compared to
previous reports.
The present study includes limitations that relate to its ret-
rospective nature. First, parameters that may influence blood
glucose were only partially documented. The retrospective
study design did not enable documentation of any ongoing
medications prior to blood culture collection. This is an evi-
dent weakness as it is well known that, in addition to diabetes
related therapies like insulin, various other medications may
cause blood glucose level fluctuations, e.g. non-steroidal anti-
inflammatory drugs may alter insulin release from beta cells
[37]. In addition, any infusion fluids administered in connec-
tion with blood culture collection were undocumented. Hence,
as some infusion fluids contain glucose it is possible that the
etiology of hyperglycemia during blood culture collection
time-point in some patients may have been iatrogenic.
Second, we recorded only one glucose measurement within
24 h of blood culture collection. The documentation of several
glucose values would have enabled more precise analysis ei-
ther (1) as an arithmetic mean of several values [26] or (2) as a
time-weighted analysis [38]. Third, the blood glucose mea-
surements, within 24 h of blood culture collection, were drawn
irrespective of time and fasting, i.e. recent intake of food or
Table 4 Cox proportional hazard regression model for prognostic factors of 90-day mortality in Staphylococcus aureus bacteraemia patients
categorized to include healthy non-diabetics (n = 91), Hazards ratio (HR), and 95% confidence intervals (95% CI)
Parameters Univariate analysis Cox regression analysis
Died
N = 8 (9%)
Survived
N = 83 (91%)
OR (95% CI) p-value HR (95% CI) p-value
Male sex 3 (38) 50 (60) 0.39 (0.09–1.77) NS – –
Age > 60 years 2 (25) 21 (25) 0.98 (0.18–5.25) NS – –
Glucose cut-off 7.2 mmol/La 6 (75) 27 (33) 6.22 (1.18–32.9) <0.05 7.46 (1.48–37.6) <0.05
Intensive care unita 5 (63) 24 (29) 4.09 (0.91–18.5) NS – –
Severe sepsisa 3 (38) 11 (13) 3.93 (0.82–18.8) NS – –
Endocarditis 3 (38) 14 (17) 2.96 (0.63–13.8) NS – –
Pneumonia 6 (75) 32 (39) 4.78 (0.91–25.2) <0.05 – –
Rifampicin therapy ≥ 14 daysb 2 (25) 54 (65) 0.18 (0.03–0.94) <0.05 – –
Bedside consultationc 2 (25) 68 (82) 0.07 (0.01–0.40) <0.001 0.07 (0.01–0.36) <0.01
Telephone consultationc 4 (50) 12 (14) 5.92 (1.30–26.9) <0.05 – –
Values are expressed as n (%), unless otherwise stated
NS non-significant
a At positive blood culture collection
bAdditional antimicrobial therapy
c Infectious specialist consultation
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liquids. Fourth, the magnitude of the n-number in the present
study (161) is slightly higher than that of two previous reports
(100–135) [24, 25], although lower than in a third study (340)
[11] on hyperglycemia and SAB. Furthermore, the retrospec-
tive nature of the study did not allow for any glycemic control
and hence further research is needed to determine whether
continuous monitoring and control of elevated glucose levels
influence the outcome of SAB.
In conclusion, despite the retrospective study design, low
n-number and lack of information regarding backgroundmed-
ication and fasting, the present study demonstrated a negative
prognostic impact of hyperglycemia in the early phase of
SAB. The negative prognostic impact was accentuated among
young and healthy non-diabetics. Future prospective studies
are needed to establish the relevance of underlying medica-
tion, fasting and glycemic control on outcome in SAB.
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